Xueyan Jiang

Practice Areas

Ms. Jiang Xueyan is a partner at the Beijing Office of Fangda Partners. Ms. Jiang's practice mainly focuses on the onshore and offshore offering and listing of securities, mergers, acquisitions and reorganizations in connection with listed companies, pricate equity investment and financing, etc.

Career

Prior to joining the Beijing Office of Fangda Partners, Ms. Jiang was a partner at a leading PRC law firm.

Personal

Honors and Awards

Listed on the Capital Markets list of Chambers and IFLR1000 for several years

Education

Experience

Representative cases of onshore and offshore issuance of securities practiced by Ms. Jiang include:

-Represented, as the issuer’s counsel, Jiangsu Huachen (603097.SH), Cowealth (603122.SH), Bank of Chongqing (601963.SH), Xinyaqiang Silicon Chemistry (603155.SH), VeriSilicon (688521.SH), AMEC (688012.SH), Wuxi AppTec (603259.SH), Avary Holding (002938.SZ), Konruns Pharmaceutical (603590.SH) in their initial public offering and listing of A shares, and Air China (753.HK), Wuxi AppTec (2359.HK) in their initial public offering and listing of H shares, SDIC Power Holdings (600866.SH) in its GDR issuance and listing on the London Stock Exchange;

-Represented the sponsor or broker, in the initial public offering and listing of A shares by Bio-Thera (688177.SH), Zelgen (688266.SH), Maxscend (300782.SZ), Foxconn Industrial Internet (601138.SH), Contemporary Amperex Technology (300750.SZ) and Bank of Ningbo (002142.SZ) , in the initial public offering and listing in Hong Kong by CSSC (3877.HK), CDB Leasing (1606.HK), Bank of Chongqing (1963.HK) and China National Building Materials Group (3323.HK), and in the initial public offering and listing on NASDAQ by Genetron Health (GTH.US);

-Represented, as the issuer’s counsel, Wuxi AppTec (603259.SH/2359.HK) in its issuance of H-share convertible bonds, private placement of H shares and non-public offering of A shares, Sinopec (600028.SH/386.HK) in its private placement of H shares and issuance of H-share convertible bonds, A-share convertible bonds with warrants and A-share convertible bonds, Bank of Chongqing (1963.HK) in its private placement of H shares and issuance of offshore preferred shares, Shenzhen Kaifa Technology (000021.SZ) in its non-public offering of A shares, Bank of Ningbo (002142.SZ) in several non-public offerings of A shares and preferred shares, public offering of A-share convertible bonds and allotment of A shares to its original shareholders, and Air China (601111.SH/753.HK) in its non-public offering of A shares;

-Represented the sponsor or broker, in the non-public offering of A shares by Maxscend Microelectronics (300782.SZ), Yiling Pharmaceutical (002603.SZ), Yibai Pharmaceutical (600594.SH), Bank of Beijing (601169.SH), the public offering of A-share convertible bonds and non-public offering of A shares by China Molybdenum Co., Ltd. (603993.SH/3993.HK), the issuance of H-share convertible bonds by CRRC Corporation (601766.SH/1766.HK), China Railway Construction Corporation (601186.SH/1186.HK), and the issuance of offshore preferred shares by Bank of Chongqing (1963.HK) and China Merchants Bank (3968.HK).

Representative cases of investment, financing, mergers and acquisitions, and joint venture practiced by Ms. Jiang:

-Represented FutureFab·Ai, Dongfang Jingyuan, Nanjing Xiezhong, Innoscience, Pactera, Data Interlink, Alpha Power, Marching Power, COFCO W&W, Cowealth Medical, Advanced Micro-Fabrication Equipment Inc., VeriSilicon, Wuxi AppTec, Avary Holding, JIC Leasing, Beijing Hebabiz Biotechnology Co., Ltd. as well as AutoAI and China Satellite Navigation and Communication Co., Ltd., MapBar, subordinated to Navinfo (002405.SZ) in the introduction of several investors; represented China Cinda in its sale of the first majority equity interest in Bank of Xi’an;

-Represented China Integrated Circuit Industry Investment Fund Co., Ltd. (“IC Fund”) in its investment in Beijing Jidian, Silan Xiamen, Changxin Jidian, Xysemi, SMIC Shenzhen, China Wafer Level CSP Co., Ltd. (603005.SH), Giga Device Semiconductor (Beijing) Inc. (603986.SH), Navtech Inc. (300456.SZ), HLMC, Shenzhen State Micro Technology Co., Ltd. (02239.HK), Ninestar Corporation (002180.SZ), Centec Networks, Advanced Micro-Fabrication Equipment Inc.; Telink and Apex Microelectronics; represented Wuxi AppTec in its acquisition of Jiangsu Safe Pharmaceutical Co., Ltd., HD Biosciences Co., Ltd.; Dalian Elite Instruments, Blooming Spring, Changchun Biology and Milestone Pharma, in its acquistition of the minority equity in STA Pharma, a once NEEQ listed company, and its delisting, and its investments in Hygeia, Xinshiyan Medical Technology, Chain Medical Labs, Cyagen and Gammastar; represented investors in their investment in or acquisition of Silicon Innovation, INGEEK, CalmCar Vehicle Vision System, Zhejiang Shell, Medical, Ximalaya, Career International, Edianzu, Pantian Techonology, BYD Semiconductor, Hongfans Technology, Tongtuo Technology;

-Represented Guanjie Technology in the cash acquisition of its 51% shares by Huadong Electronics (000727.SZ) and the sale of all assets, Sichuan Haowu Electromechanical Co., Ltd. in its issuance of shares and payment of cashes for acquisition of Neijiang Pengxiang Investment Co., Ltd.; represented Sinopec in its mixed ownership reform of sales segments; represented Sinopec Yizheng Chemical Fibre Co., Ltd. (600871.SH/1033.HK) in its assets swap with Sinopec Oilfield Service Corporation; represented Tsinghua Unigroup in the acquisition of Spreadtrum, a U.S. listed company, represented Sinopec in its acquisition of A-share listed companies, Sinopec Qilu Petrochemical Company Ltd., Sinopec Yangzi Petrochemical Co., Ltd., Sinopec Zhongyuan Petroleum Co., Ltd. and Sinopec Shengli Oil Field Dynamic Group Co., Ltd. by tender offer; represented Sinopec in its merger of H-share listed companies, Sinopec Beijing Yanhua Petrochemical Company Limited and Sinopec Zhenhai Refining & Chemical Company Limited;

-Represented CICC, IC Fund, Sinopec, Wuxi AppTec, VeriSilicon Microelectronics (Shanghai) Co., Ltd. and other companies in the establishment of joint ventures in respect of asset management, medical big data, manufacture and design of integrated circuit, together with their cooperators.